TY - JOUR
TI - Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study
AU - Bougea, A.
AU - Koros, C.
AU - Papagiannakis, N.
AU - Simitsi, A.-M.
AU - Prentakis, A.
AU - Papadimitriou, D.
AU - Pachi, I.
AU - Antonelou, R.
AU - Angelopoulou, E.
AU - Beratis, I.
AU - Bozi, M.
AU - Papageorgiou, S.G.
AU - Trapali, X.G.
AU - Stamelou, M.
AU - Stefanis, L.
JO - Journal of Parkinson's Disease
PY - 2021
VL - 11
TODO - 2
SP - 633-640
PB - IOS Press BV
SN - 1877-7171, 1877-718x
TODO - 10.3233/JPD-202337
TODO - leucine rich repeat kinase 2;  uric acid;  biological marker;  leucine rich repeat kinase 2;  LRRK2 protein, human;  uric acid, adult;  aging;  Article;  body mass;  cohort analysis;  comparative study;  controlled study;  disease severity;  female;  follow up;  Geriatric Depression Scale;  human;  longitudinal study;  LRRK2 gene;  major clinical study;  male;  middle aged;  Montreal cognitive assessment;  Parkinson disease;  pathogenesis;  priority journal;  sex ratio;  Unified Parkinson Disease Rating Scale;  uric acid blood level;  aged;  chemistry;  genetics;  metabolism;  mutation;  Parkinson disease, Aged;  Biomarkers;  Humans;  Leucine-Rich Repeat Serine-Threonine Protein Kinase-2;  Mutation;  Parkinson Disease;  Uric Acid
TODO - Background: Previous studies have highlighted serum uric acid as a putative idiopathic Parkinson's disease (iPD) biomarker. Only one study, so far, showed higher levels of serum uric acid in leucine-rich repeat kinase 2 (LRRK+2) carriers compared to those who developed PD, however a longitudinal comparison between LRRK2+PD and healthy controls (HC) has not been performed. Objective: The aim of this study was to determine whether there are longitudinal differences in serum uric acid between iPD, LRRK2+PD and HC and their association with motor and non-motor features. Methods: Longitudinal data of uric acid of 282 de novo iPD, 144 LRRK2+PD patients, and 195 age-matched HC were obtained from the Parkinson's Progression Markers Initiative (PPMI) database. We also used longitudinal Montreal Cognitive Assessment (MoCA), Movement Disorder Society-Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS-III), Geriatric Depression Scale (GDS) scores, and DaTSCAN striatal binding ratios (SBRs). Results: Longitudinal uric acid measurements were significantly lower in LRRK2+PD patients compared to HC up to 5 years follow-up. There was no significant impact or correlation of adjusted or unadjusted uric acid levels with MoCA, MDS-UPDRS III, or GDS scores, the presence of RBD or DAT-SCAN SBRs. Conclusion: LRRK2+PD group had significantly lower uric acid concentrations compared to HC after adjusting for age, sex and baseline BMI up to 5 years follow-up. There were no significant associations between uric acid levels and indices of disease severity. These findings identify serum uric acid as a marker linked to LRRK2+PD. © 2021 - IOS Press. All rights reserved.
ER -